A pioneer experience in Malaysia on In-house Radio-labelling of 131I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose 131I-rituximab-BEAM conditioning autologous transplant.

Radioimmunotherapy is an established treatment modality in Non-Hodgkin's lymphoma. The only two commercially available radioimmunotherapies – 90 Y-ibritumomab tiuxetan is expensive and 131 I-tositumomab has been discontinued from commercial production. In resource limited environment, self-labelling 131 I-rituximab might be the only viable practical option. We reported our pioneer experience in Malaysia on self-labelling 131 I-rituximab, substituting autologous haematopoietic stem cell transplantation (HSCT) and a patient, the first reported case, received high dose 131 I-rituximab (6000 MBq/163 mCi) combined with BEAM conditioning for autologous HSCT. [ABSTRACT FROM AUTHOR]